One Medical under congressional investigation after reports of selling vaccines to the wealthy -
kusi.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kusi.com Daily Mail and Mail on Sunday newspapers.
Vaccine Misallocations Sparks One Medical Congressional Hearing
kuer.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kuer.org Daily Mail and Mail on Sunday newspapers.
Originally published on March 2, 2021 10:56 am
The consequences are deepening for concierge health care provider One Medical following an NPR investigation that found the company administered COVID-19 vaccinations to those with connections to leadership, as well as ineligible patients.
The House Select Subcommittee on the Coronavirus Crisis is launching its own investigation into the San Francisco-based company s practices, NPR has learned. The probe has plunged the publicly traded company, whose business model depends on patients paying a $199 annual fee for VIP health care services, into damage control mode. Despite being warned that the company s lax oversight of vaccine eligibility rules was allowing ineligible patients to jump the line, One Medical has reportedly failed to properly implement an effective protocol to verify eligibility and instructed staff not to police eligibility, wrote subcommittee chairman James Clyburn in a letter sent to One Medical late Monday night.
Michael A. McCoy/Pool/Getty Images
hide caption
toggle caption Michael A. McCoy/Pool/Getty Images
Rep. James Clyburn, pictured last October, is chairman of the House Select Subcommittee on the Coronavirus Crisis, which is launching its own investigation into One Medical s vaccine practices. Michael A. McCoy/Pool/Getty Images
The consequences are deepening for concierge health care provider One Medical following an NPR investigation that found the company administered COVID-19 vaccinations to those with connections to leadership, as well as ineligible patients.
The House Select Subcommittee on the Coronavirus Crisis is launching its own investigation into the San Francisco-based company s practices, NPR has learned. The probe has plunged the publicly traded company, whose business model depends on patients paying a $199 annual fee for VIP health care services, into damage control mode.